AzTrials
AzTrials

Diabetes Mellitus, Type 2NCT05787457

Comparative Metabolomics in Diabetes Patients From Sri Lanka and Switzerland

An observational study of Diabetes Mellitus, Type 2, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study is a case-control study, where the assumed different subtypes of type 2 diabetes in people of Tamil ethnicity and Swiss origin living in Bern, Switzerland will be examined by measuring the metabolite profiles and the corresponding genetic background as well as ethnic differences in fat distribution… Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Diabetes Mellitus, Type 2
What is being tested?
Clinical examination, Blood testing and MRI
How many people
34 participants
Where
1 siteSwitzerland
Study dates
31 Jul 2014to 30 Sep 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population consists of thirty Tamils and sixty native Swiss people with type 2 diabetes.

Who may be able to join

  • Diagnosed with type 2 diabetes per WHO criteria.
  • Swiss ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Switzerland)
  • Tamil ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Sri Lanka, belonging to ethnic identity of Tamils, respectively)
  • Age limit: 18 - 75 years

Who cannot join

  • Subjects with type 1 diabetes, steroid-induced diabetes, gestation diabetes, or pancreoprivic diabetes.
  • Subjects with pregnancy.
  • Subjects with metal implant, tattoos, or claustrophobia. MRI must be feasible.
  • Subjects with severe chronic diseases, e.g. malignancies, heart or renal diseases (> stage 3).
  • Subjects not able to provide informed consent.
  • Enrolled in another study.

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • University Hospital Inselspital, Berne

    Bern, 3011

Other trials in Switzerland

About this study

This study is a case-control study, where the assumed different subtypes of type 2 diabetes in people of Tamil ethnicity and Swiss origin living in Bern, Switzerland will be examined by measuring the metabolite profiles and the corresponding genetic background as well as ethnic differences in fat distribution performed by magnetic resonance imaging (MRI). The investigators aim to show that the specific metabolite profile and the fat distribution in the Tamil population is associated with the high prevalence of diabetes in this ethnicity. Fat distribution patterns are thought to determine the expression and severity of dysglycaemia. Additionally, the investigators aim to identify the key enzymes, their corresponding genes, and the respective polymorphisms relevant for these metabolic variations.

Read the detailed description

Over the last two decades, the prevalence of type 2 diabetes has exploded among native and migrant South Asian populations. The earliest available epidemiological study in a rural sector in Sri Lanka showed a diabetes prevalence of 2.5% in 1990. In 2008 the Sri Lanka Diabetes, Cardiovascular Study (SLDCS) reported a prevalence of 10.3% for Sri Lankans aged ≥ 20 years. South Asian migrants living in western countries have higher diabetes prevalence rates compared with indigenous populations, around 10-14% in Europeans, 25-34% in Indian Asians. Moreover, type 2 diabetes develops at younger age in Asians than in Caucasian populations. In the UK the relative risk of type 2 diabetes in South Asian children is 14 times greater than in children of European descent.

A popular hypothesis for the greater prevalence of type 2 diabetes is that South Asians are undergoing rapidly changes in demographic profile, increasing urbanization and development and adoption of modern ("westernized") lifestyle. Nutrition transition, adoption of a sedentary lifestyle, reduced physical activity and possibly mental and social stress are held responsible for this increase. Especially the effect of dietary changes with higher intakes of sugars, animal fats and vegetable oils is large and most of the emerging epidemic of chronic disorders, like diabetes mellitus, are diet related. It has been detected that obesity induces excess lipolysis causing increased concentration of non-esterified fatty acids and triglycerides in blood and skeletal muscle. Lipotoxicity plays an important role in inducing insulin resistance and β-cell damage. Furthermore it has been observed that the kind of fat distribution correlates with the expression and the severity of dysglycaemia and that there are marked ethnic differences in fat distribution.

For example people of both South Asian and African Caribbean descent have an elevated risk of diabetes compared to Europeans. But while South Asians are centrally obese, dyslipidaemic and vulnerable to cardiac disease, African Caribbeans do not exhibit the diabetes related dyslipidaemic profile. A potential explanation for this discrepancy may lie in ethnic differences in fat distribution.

But it is not clear whether this can completely be attributed to ethnic differences, because features of insulin resistance, hypertriglyceridaemia, and hyperinsulinaemia are seen even in non-obese South Asian individuals. In contrast to Caucasian diabetic patients having a much higher BMI than the nondiabetic Caucasian population, the average BMI of Asians with diabetes is similar to the non-diseased population, indicating that South Asians diabetic patients in average are not obese. South Asians, however, have a much greater tendency to deposit intra-abdominal fat, which is metabolically active and strongly related to insulin resistance. Furthermore South Asians are proportionally fat due to less non-fat tissues. Therefore, insulin resistance in people of South Asian origin can occur even in the absence of conventionally defined obesity. The development of type 2 diabetes linked to obesity caused by overnutrition, which is regarded as a common feature in the Caucasian population, may not be typical in South Asians. This points at the limitations of BMI as a measure of adiposity across populations. These specific clinical characteristics, including a high degree of insulin resistance associated with abdominal fat deposition without massive obesity are common in patients of South Asian descent.

These findings suggest that Asians are more vulnerable than other ethnic groups to type 2 diabetes in response to a relatively small increase in body weight. Genetic susceptibility may be responsible for high prevalence of insulin resistance in South Asians . Such an escalating prevalence of type 2 diabetes is unlikely to be explained by genetic factors, indicating a greater influence of environmental factors in disease aetiology. Nevertheless type 2 diabetes has a strong genetic component. Most Asian diabetes patients have first-degree relative with diabetes. Several genetic variants have been identified by genome-wide association studies. Most genetic variants linked to type 2 diabetes seem to be related to insulin secretion rather than insulin resistance. In South Asian populations, however, the burden is the increased susceptibility to develop insulin resistance due to genetic predisposition and/or in response to certain environmental influences. These findings are showing the need for populations-specific studies. For this reason, the investigators restrict the study to the Tamil ethnic group living in Bern, Switzerland, with a Swiss reference cohort. The Tamil ethnicity is an isolated population with high prevalence of type 2 diabetes. Cultural customs have preserved this population from ethnic admixture. The first and the most of the second generation of migrated Tamils still belong to a population with a homogeneous genetic background, which facilitate to identify complex trait-susceptibility genes.

In contrast to many previous genome-wide association studies an inverse approach is taken for this study. The primary objective of this study is to show changes in the metabolic concentrations in plasma between Tamil individuals and native Swiss population using a mass-spectrometric approach. Type 2 diabetics have specific metabolic variations, and the investigators assume that South Asians and Caucasians differ in these alterations. The secondary aim of this study is to identify the key enzymes, their corresponding genes, and the respective polymorphisms relevant for the metabolic variations using a metabolic-pathway-based search including also intronic variants commonly missed by SNP (single nucleotide polymorphism)-and haplotype-analysis.

Being tested
Clinical examination, Blood testing, MRI
Keywords
Native South Asian population, Migrant South Asian population, Swiss ethnicity, Tamil ethnicity, Body fat distribution, Type 2 Diabetes, Magnetic resonance imaging, Genetic predisposition, Genetic background, Metabolomics, Non-targeted mass spectrometry, Insulin resistance, Hypertriglyceridaemia, Hyperinsulinaemia
Medical subject headings
Diabetes Mellitus, Type 2, Genetic Predisposition to Disease, Insulin Resistance, Hypertriglyceridemia, Hyperinsulinism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Clinical examinationOther

  • Blood testingOther

  • MRIOther

Study groups in NCT05787457
Study groupRoleWhat they receive
Tamil natives with Diabetes Type 2Thirty Tamil natives (15 men, 15 women), representing general Tamil diabetic cohort.
Receives: Other: Clinical examination; Other: Blood testing; Other: MRI
Swiss natives with Diabetes Type 2_matchedThirty Swiss natives (15 men, 15 women) matching the Tamil cohort.
Receives: Other: Clinical examination; Other: Blood testing; Other: MRI
Swiss natives with Diabetes Type 2_not matchedThirty Swiss natives (15 men, 15 women), who are not matched to the Tamil cohort, representing general Swiss diabetic cohort.
Receives: Other: Clinical examination; Other: Blood testing; Other: MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Metabolic phenotype of type 2 diabetes mellitus across groups

    Significant metabolic changes in blood plasma of type 2 diabetic patients compared across groups as quantified by mass-spectrometric analysis

    Measured: At baseline

Secondary outcomes (1)
  1. Genetic Differences

    Frequency of single nucleotide polymorphisms across groups

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2023
  2. Study start31 Jul 2014
  3. Primary completion30 Sep 2021
  4. Study completion30 Sep 2021

Why it stopped: Insufficient recruitment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
34 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05787457
Sponsor's protocol ID
KEK-203/13
Other IDs
2527
Status last verified
Mar 2023
First submitted
20 Apr 2016
Last updated
28 Mar 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Sharing data depends on institutional (sponsor) and ethics agreement.

Publications

  • Abate N, Carulli L, Cabo-Chan A Jr, Chandalia M, Snell PG, Grundy SM. Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J Clin Endocrinol Metab. 2003 Dec;88(12):5927-34. doi: 10.1210/jc.2003-030453.

    PubMed 14671192
  • Barnett AH, Dixon AN, Bellary S, Hanif MW, O'hare JP, Raymond NT, Kumar S. Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia. 2006 Oct;49(10):2234-46. doi: 10.1007/s00125-006-0325-1. Epub 2006 Jul 18.

    PubMed 16847701
  • Ehtisham S, Crabtree N, Clark P, Shaw N, Barrett T. Ethnic differences in insulin resistance and body composition in United Kingdom adolescents. J Clin Endocrinol Metab. 2005 Jul;90(7):3963-9. doi: 10.1210/jc.2004-2001. Epub 2005 Apr 19.

    PubMed 15840754
  • Illangasekera U, Nugegoda DB, Perera LS. Prevalence of diabetes mellitus and impaired glucose tolerance in a rural Sri Lankan community. Ceylon Med J. 1993 Sep;38(3):123-6.

    PubMed 7828231
  • Illangasekera U, Rambodagalla S, Tennakoon S. Temporal trends in the prevalence of diabetes mellitus in a rural community in Sri Lanka. J R Soc Promot Health. 2004 Mar;124(2):92-4. doi: 10.1177/146642400412400214.

    PubMed 15067982
  • Jourdan C, Petersen AK, Gieger C, Doring A, Illig T, Wang-Sattler R, Meisinger C, Peters A, Adamski J, Prehn C, Suhre K, Altmaier E, Kastenmuller G, Romisch-Margl W, Theis FJ, Krumsiek J, Wichmann HE, Linseisen J. Body fat free mass is associated with the serum metabolite profile in a population-based study. PLoS One. 2012;7(6):e40009. doi: 10.1371/journal.pone.0040009. Epub 2012 Jun 27.

    PubMed 22761945
  • Katulanda P, Constantine GR, Mahesh JG, Sheriff R, Seneviratne RD, Wijeratne S, Wijesuriya M, McCarthy MI, Adler AI, Matthews DR. Prevalence and projections of diabetes and pre-diabetes in adults in Sri Lanka--Sri Lanka Diabetes, Cardiovascular Study (SLDCS). Diabet Med. 2008 Sep;25(9):1062-9. doi: 10.1111/j.1464-5491.2008.02523.x.

    PubMed 19183311
  • Katulanda P, Sheriff MH, Matthews DR. The diabetes epidemic in Sri Lanka - a growing problem. Ceylon Med J. 2006 Mar;51(1):26-8. doi: 10.4038/cmj.v51i1.1373.

    PubMed 16898034
  • Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010 Jan 30;375(9712):408-18. doi: 10.1016/S0140-6736(09)60937-5. Epub 2009 Oct 28.

    PubMed 19875164
  • Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes. 2001 Feb;50 Suppl 1:S118-21. doi: 10.2337/diabetes.50.2007.s118.

    PubMed 11272168
  • Vandenheede H, Deboosere P, Stirbu I, Agyemang CO, Harding S, Juel K, Rafnsson SB, Regidor E, Rey G, Rosato M, Mackenbach JP, Kunst AE. Migrant mortality from diabetes mellitus across Europe: the importance of socio-economic change. Eur J Epidemiol. 2012 Feb;27(2):109-17. doi: 10.1007/s10654-011-9638-6. Epub 2011 Dec 14.

    PubMed 22167294

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Mellitus, Type 2, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 28 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Insufficient recruitment). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Metabolic phenotype of type 2 diabetes mellitus across groups (time frame: At baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05787457, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in